600351 亚宝药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)7.5638.2706.7133.5496.558
总资产报酬率 ROA (%)6.2476.5614.9992.5504.625
投入资产回报率 ROIC (%)7.0857.5445.7892.9265.251

边际利润分析
销售毛利率 (%)52.13551.68157.85455.87561.030
营业利润率 (%)14.82211.1677.7784.5457.352
息税前利润/营业总收入 (%)14.68110.8457.6375.0217.828
净利润/营业总收入 (%)11.6168.3366.1833.8486.649

收益指标分析
经营活动净收益/利润总额(%)113.121100.817131.986142.17888.166
价值变动净收益/利润总额(%)1.043-1.039-2.441-3.3217.378
营业外收支净额/利润总额(%)0.041-2.686-3.3581.671-0.806

偿债能力分析
流动比率 (X)3.1362.6792.2321.8781.787
速动比率 (X)2.4931.9691.6691.4461.269
资产负债率 (%)17.52418.31422.32527.21927.304
带息债务/全部投入资本 (%)3.9614.4088.60214.20016.253
股东权益/带息债务 (%)2,371.8342,119.6861,036.449588.042500.797
股东权益/负债合计 (%)477.277445.691345.935264.142262.957
利息保障倍数 (X)-99.804-357.87068.94012.60314.655

营运能力分析
应收账款周转天数 (天)41.41442.16248.28256.80158.155
存货周转天数 (天)118.411118.605130.818145.597170.291